Oral contraception does not alter single dose saquinavir pharmacokinetics in women

British Journal of Clinical Pharmacology

Volumn 57, Issue 3, 2004, Pages 244-252

  Fröhlich, Margit ^a   Burhenne, Jürgen ^a   Martin Facklam, Meret ^a   Weiss, Johanna ^a   Von Wolff, Michael ^a   Strowitzki, Thomas ^a   Walter Sack, Ingeborg ^a   Haefeli, Walter E ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYP3A; Drug interaction; Oral contraception; P glycoprotein; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A; DRUG METABOLITE; ESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; FOLLITROPIN; GELATIN; GLYCOPROTEIN P; LUTEINIZING HORMONE; MULTIDRUG RESISTANCE PROTEIN 1; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROTEINASE INHIBITOR; SAQUINAVIR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MASS SPECTROMETRY; MENSTRUAL CYCLE; NORMAL HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; SEX RATIO; SINGLE DRUG DOSE;

EID: 1542299795     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2003.01983.x     Document Type: Article

References (50)

1. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1-6.
2. Heinemann K, Moehner S, Lewis M, Assmann A, Garbe E, Heinemann LA. Trends of OC use 1980-99 in a German cohort of women. Zentralbl Gynakol 2002; 124: 128-31.
3. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-7.
5. Nguyen ML, Nagy GS, Hernandez I, Holtzberg J, Del Rio C, Lennox J.Use of HAART in women: similar response but greater toxicity. XIV. International AIDS Conference, Barcelona 2002: Abstract WePeB5968.
6. Bonfanti P, Valsecchi L, Parazzini F et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr 2000; 23: 236-45.
7. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Jeuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol 2000; 50: 333-7.
8. Balogh A, Gessinger S, Svarovsky U et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pyridine metabolite in humans? Eur J Clin Pharmacol 1998; 54: 729-34.
9. Deray G, le Hoang P, Cacoub P, Assogba U, Grippon P, Baumelou A. Oral contraceptive interaction with cyclosporin. Lancet 1987; 1: 158-9.
10. Gustavson LE, Legler UF, Benet LZ. Impairment of prednisolone disposition in women taking oral contraceptives of conjugated estrogens. J Clin Endocrinol Metab 1986; 62: 234-7.
11. Belle DJ, Callaghan JT, Gorski JC et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestel on CYP3A activity. Br J Clin Pharmacol 2002; 53: 67-74.
12. Orme MLE, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983; 8: 95-136.
13. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188-215.
14. Testa B, Jenner P. Inhibitors of cytochrome P450s and their mechanism of action. Drug Metab Rev 1981; 12: 1-117.
15. Guengerich FP. Oxidation of 17a-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500-8.
16. Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-71.
17. Ortiz de Montellano PR, Correia MA. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Ann Rev Pharmacol Toxicol 1983; 23: 481-503.
18. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-7.
19. Barnes KM, Dickstein B, Cutler GB, Fojo T, Bates SE. Steroid transport, accumulation, and antagonism of p-glycoprotein in multidrug-resistant cells. Biochemistry 1996; 35: 4820-7.
20. Brundage RC, Acosta E, Haubrich R, Katzenstein D, Gulick R, Fletcher CV. Quantitation of sex differences and drug interactions, pharmacologic studies of saquinavir (SQV) in ACTG 2002, 359. 9th Conference on Retroviruses and Opportunistic Infections: (Abstract) 779-W.
21. CDER New and Generic Drug Approvals. 1998-2003: Product Label Invirase® (Saquinavir Mesylate). Capsules, Hoffman-La Roche, Inc. Available at: URL. http://www.fda.gov/cder/approval/index.htm.AccessedJuly 2003, 08.
22. Eagling VA, Wiltshire H, Whitcombe IW, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 2002; 32: 1-17.
23. Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 289-94.
24. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatine capsules) administration. Br J Clin Pharmacol 2001; 52: 255-64.
25. Burhenne J, Riedel K-D, Martin-Facklam M, Mikus G, Haefeli WE. Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2003; 784: 233-42.
26. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25: 256-66.
27. Nauck M, Stein U, von Karger S, März W, Wieland H. Rapid detection of the C3435T polymorphism of multidrug resistance gene 1 using fluorogenic hybridization probes. Clin Chem 2000; 46: 1995-7.
28. Cascorbi I, Gerloff T, Johne A et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-74.
29. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3347.
30. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189-99.
31. Martin-Facklam M, Burhenne J, Ding R et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol 2002; 53: 576-81.
32. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93-112.
33. Kitchen VS, Skinner C, Ariyoshi K et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5.
34. Mitsuyasu RT, Skolnik PR, Cohen SR et al. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. AIDS 1998; 12: F103-F109.
35. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20: 147-69.
36. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355-9.
37. Yasuda K, Lan L-B, Sanglard D, Furuya K, Schuetz JD, Schuetz EG. Interaction of cytochrome P450 2002, 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303: 323-32.
38. Woodcock DM, Jefferson S, Linsenmeyer ME et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990; 50: 4199-203.
39. Goodwin B, Ridinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Tocicol 2002; 42: 1-23.
40. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-8.
41. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 1998, 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87: 1322-8.
42. Vella S, Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 1998; 34: 189-201.
43. Figgitt DP, Plosker GL. Saquinavir soft-gel capsule. An updated review of its use in the management of HIV infection. Drugs 2000, 2002; 60: 481-516.
44. Kurowski M, Sternfeld T, Hill A, Sawyer AW, Moecklinghoff C. Comparative pharmacokinetics and short-term safety of Fortovase®/ritonavir and Invirase®/ritonavir 1000mg/100mg BID. 9th Conference on Retroviruses and Opportunistic Infections: Abstract 432-W.
45. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52: 255-64.
46. Purba HS, Maggs JL, Orme MLE, Back DJ, Park BK. The metabolism of 17a-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br J Clin Pharmac 1987; 23: 447-53.
47. Böcker R, Kleingeist B, Eichhorn M, Lepper H. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contracept 1991; 7(Suppl 3): 140-8.
48. Back DJ, Houlgrave R, Tjia JF, Ward S, Orme MLE. Effect of the progestogens, gestodene, 3-ketodesogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Molec Biol 1991; 38: 219-25.
49. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 1984; 36: 683-90.
50. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.